Our data showed that higher levels of DDOST expression were associated with fewer tumor-infiltrating B cells and CD4+ T cells in glioma, which meant that less tumor-infiltrating B cells were unable to activate a powerful antitumor immune response and induce immune escape, which, in turn, led to a poorer prognosis. This evidence concerns the gene CD4 and central nervous system cancer.